Fulgent Genetics, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stoc kholder Matters and Issuer Purchases of Equity Securities. Market Information On September 29, 2016, our common stock was listed for trading on Nasdaq under the symbol “FLGT.” There was no public market for our common stock prior to September 29, 2016. Holders of Common Stock As of February 1, 2026, there were 11 holders of record of our common stock, plus an indeterminate number of additional stockholders whose shares of our common stock are held on their behalf by brokerage firms or other agents. Dividend Policy We currently anticipate that we will retain any future earnings to finance the continued development, operation and expansion of our business. As a result, we do not anticipate declaring or paying any cash dividends or other distributions in the foreseeable future. Any determination to pay dividends would be at the discretion of our board of directors and would depend on our results of operation, financial condition and other factors that our board of directors, in its discretion, considers relevant . Common Stock Performance Graph The following graph compares the cumulative total stockholder return, calculated on a dividend-reinvested basis, in our common stock, the Nasdaq Composite Index, and the Nasdaq Biotechnology Index for the five years ended December 31, 2025. The comparison assumes that $100 was invested in our common stock, the NASDAQ Composite Index, and the Nasdaq Biotechnology Index as of the market close on December 31, 2020. Note that historic stock price performance is not necessarily indicative of future stock price performance. 75 Information on Share Repurchases There were no shares of common stock purchased during the three months ended December 31, 2025. For further information about shares repurchased, see Note 16, Stock Repurchase Program , to our consolidated financial statements. Item 6. [R eserved] 76